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Abstract
Purpose To evaluate the safety and efﬁcacy of two dif-
ferent methods of proximal cystic artery embolization in
patients undergoing yttrium-90 radioembolization.
Materials and Methods Forty-six patients had cystic
artery embolization performed immediately before yttrium-
90 radioembolization, either by using Gelfoam pledgets
(n = 35) or coils (n = 11). Clinical symptomatology dur-
ing the admission and angiographic ﬁndings at 1-month
follow-up were retrospectively reviewed. Rates of collat-
eralization or recanalization of the cystic artery were
compared, as well as the frequency of postprocedural
abdominal pain and need for cholecystectomy.
Results Technical success was achieved in all patients,
and there were no procedural complications related to
cystic artery embolization. Of the 11 coil-embolized
patients, 5 (45%) demonstrated collateralization of the
cystic artery at 1 month, and 1 (9%) demonstrated recan-
alization of the cystic artery. Of the 35 Gelfoam-embolized
cases, 2 (6%) had collateralized at 1 month, and 14 (40%)
had recanalized. Two patients (one from each group) had
self-limited right upper quadrant pain after the procedure,
and one patient in the coil embolization group required
cholecystectomy.
Conclusion Proximal cystic artery embolization is safe
and feasible and may be performed during liver-directed
embolotherapy to minimize the exposure of the gallbladder
to particulate, chemoembolic, or radioembolic agents.
Keywords Cystic  Embolization  Yttrium 
Radioembolization
Introduction
Yttrium-90 radioembolization is an effective technique for
treatment of primary and secondary liver tumors [1–8]. A
feared complication of the procedure is nontarget emboli-
zation of the radiopharmaceutical, which can result in
severe damage to the stomach, duodenum, or pancreas.
Nontarget embolization to the gastrointestinal tract is
avoided by preprocedure coil embolization of the relevant
splanchnic arteries [9–11].
Nontarget embolization of the gallbladder is also a
concern during hepatic embolotherapy. Chemical or
ischemic cholecystitis may result from transarterial chemo-
embolization or transarterial embolization, with occasional
clinical sequelae including cholecystitis, cholecystectomy,
and a trend to more severe postembolization syndrome
[12–16]. Similarly, radiation cholecystitis may occur after
radioembolization, and though it is usually subclinical,
studies suggest it contributes to postprocedure morbidity,
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During radioembolization, gallbladder protection is
usually afforded by lobar infusion distal to the cystic artery
origin. However, a high incidence of cystic artery variation
has been observed [20–22] which may complicate or pre-
clude distal infusion. Also, infusion too distal in the lobar
artery may prevent symmetric distribution of the radio-
pharmaceutical [23]. Prophylactic embolization of the
cystic artery may be desirable in order to optimize the point
of radiopharmaceutical administration or simplify dose
planning.
In this study, gallbladder protection was attempted by
using either Gelfoam or coil embolization of the cystic
artery immediately before radioembolization. Periproce-
dural and postprocedural clinical course of the patients, as
well as angiographic appearance of the embolized cystic
artery at 1-month follow-up, were examined.
Materials and Methods
Patient Characteristics
Forty-six consecutive patients (31 male, 15 female; age
range 27–72 years, median 47 years) admitted for sequen-
tial lobar yttrium-90 radioembolization over a 1-year period
at a single institution were retrospectively reviewed.
Twenty-seven patients had hepatocellular carcinoma, and
19 patients suffered from metastatic liver disease, primarily
from colorectal carcinoma. Institutional review board
approval for this retrospective analysis was granted.
Preprocedure
Informed consent was obtained, which included mesenteric
angiography, embolization, and radioembolization proce-
dures. All patients underwent standard workup and evalu-
ation, including history, physical, and relevant laboratory
tests. A dedicated triple-phase computed tomographic scan
was performed to map the relevant arterial anatomy and aid
in treatment planning.
Mesenteric Angiography
Mesenteric angiography and vascular optimization was
performed per institutional protocol [9]. Moderate sedation
was induced, and the common femoral artery was accessed.
Superselective angiography of the right and left hepatic
arteries was performed, with injection rates that allowed for
reﬂux into the proximal order vessel. Vascular optimization
of the gastroduodenal artery, right gastric artery, falciform
artery, gastrohepatic trunk, accessory left hepatic artery,
supraduodenal artery, and replaced right hepatic artery was
performed as necessary, utilizing coils and/or Gelfoam
pledgets. Technetium-99m macroaggregated albumin
(
99mTc-MAA) scanning via planar single-photon emission
computed tomography (SPECT) was performed to detect
any unobserved splanchnic ﬂow and to estimate pulmonary
shunt. At the time of mesenteric angiography, the cystic
artery was identiﬁed, but not embolized.
Cystic Artery Embolization and Right Hepatic Artery
Radioembolization
Seven to 21 days after the mesenteric mapping, the patients
returned for right lobe radioembolization (all patients
underwent sequential lobar administration). At this time,
the cystic artery, and accessory vessels, when present, were
superselected with a microcatheter (Renegade Hi-Flo,
Boston Scientiﬁc, Natick, MA or Progreat Omega, Terumo,
Somerset, NJ), and embolization of the proximal cystic
artery was performed to stasis with either absorbable gelatin
sponge pledgets (Gelfoam, Pﬁzer, New York, NY) (n = 35)
or ﬁbered microcoils (VortX-18, Boston Scientiﬁc, Natick,
MA) (n = 11), at the operator’s discretion. Gelfoam
embolization technique involved cutting a small pledget of
noncompressed Gelfoam of approximately 3 mm length
and 1.5 mm width, rolling it between the ﬁngers and back-
loading it into a 1 cc syringe of contrast. The syringe was
wet-mounted to the microcatheter, which had been preﬂu-
shed with saline, and the pledget was injected with mod-
erate force under ﬂuoroscopic guidance. With either
embolization technique, a subsequent postembolization
angiogram was performed immediately proximal to the
cystic artery to conﬁrm lack of opaciﬁcation of the gall-
bladder. Selective radioembolization of the right hepatic
artery then proceeded routinely.
Postprocedure Care and Clinical Follow-up
Routine postprocedure care was provided, including over-
night admission with close observation and pain and nau-
sea control. The presence of right upper quadrant pain
and positive Murphy’s sign was recorded, if present, and
presence of these symptoms prompted observation and
surgical consultation. The need for cholecystectomy was
dictated by progressive symptoms and discretion of the
surgeon. Upon discharge, patients were instructed to con-
tact the ofﬁce for increasing pain, nausea, or fever.
Angiographic Follow-up
Approximately 1 month after the cystic artery emboliza-
tion and right hepatic radioembolization procedure,
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artery. This procedure commenced with proper hepatic
angiography, with attention to the status of the previously
embolized cystic artery. The status of gallbladder supply
was described as persistent occlusion, if no ﬂow to the
gallbladder was seen; recanalization, if the embolized
cystic artery had reconstituted; or collateralization, if new
arterial feeders to the gallbladder had developed.
Statistical Analysis
The status of gallbladder supply at follow-up was classiﬁed
as either a favorable outcome (persistent occlusion or
recanalization) or an adverse outcome (collateralization or
cholecystectomy) for each patient. The outcomes of the
coil embolization group were then compared to the out-
comes of the Gelfoam embolization group by Fisher’s
exact test. The level of signiﬁcance used was P\0.05.
Results
Technical success, deﬁned as complete embolization of the
cystic artery immediately before right hepatic radioembo-
lization, was achieved in all patients. No cystic artery
perforations were noted.
Clinical Consequence
Two patients in the coil embolization group suffered right
upper quadrant abdominal pain and positive Murphy’s sign
after the procedure. One patient was successfully treated
conservatively, while the second patient had progressive
symptoms and required cholecystectomy.
One patient in the Gelfoam embolization group suffered
right upper quadrant abdominal pain and positive Murphy’s
sign after the procedure. This patient was managed con-
servatively with eventual resolution of symptoms. No
patients in the Gelfoam embolization group required
operative intervention.
Fate of the Embolized Cystic Artery
The status of the embolized cystic artery at 1-month
angiographic follow-up is summarized in Fig. 1. In the coil
embolization group, 1 patient (9%) required cholecystec-
tomy before angiographic follow-up. Four (36%) of the 11
patients demonstrated persistent absence of ﬂow to the
gallbladder at 1-month follow-up, and 1 patient (9%)
demonstrated recanalization of the coil-embolized cystic
artery. Five patients (45%) demonstrated interval devel-
opment of small collateral vessels supplying the gallblad-
der (Fig. 2).
In the Gelfoam embolization group, 19 (54%) of 35
patients demonstrated persistent absence of ﬂow to the
gallbladder at 1-month follow-up. Two patients (6%)
demonstrated collateralization of ﬂow. Fourteen patients
(40%) demonstrated interval recanalization (Fig. 3).
Patients treated with Gelfoam embolization were more
likely to have a favorable outcome (persistent occlusion or
recanalization) at angiographic follow-up compared to
coil-embolized patients (94% vs. 45%, P = 0.001).
Conclusions
Nontarget embolization of the gallbladder has been a fre-
quent topic of discussion since the advent of hepatic arte-
rial embolization procedures as a result of its proximity to
the hepatic arterial supply. Gallbladder infarction is com-
mon when the cystic artery is occluded during chemo-
embolization, and the severity of infarction may correlate
with the severity of postprocedural abdominal pain [14,
15]. With improvements in microcatheter technology and
the trend toward superselective embolization, gallbladder
infarction from lobar or whole liver transarterial chemo-
embolization became less relevant.
The development of yttrium-90 radioembolization, in
which lobar administration of the radiopharmaceutical is
standard protocol, has again brought nontarget emboliza-
tion to the forefront of clinical concern. The gastroduode-
nal artery and right gastric artery are often protectively
coil-embolized before radioembolization; this approach has
proven quite safe thanks to the rich collateral networks in
these vascular beds. Oversight or lack of embolic protec-
tion manifests as gastric or duodenal ulcers, which can be
severe [11, 18]. The cystic artery, however, is an end artery
and has not been routinely protected before radioemboli-
zation as a result of concerns of gallbladder infarction. Not
surprisingly, imaging ﬁndings of radiation cholecystitis are
detected in up to 24% of patients after right lobe radio-
embolization [5]. Almost all of these patients can be
Fig. 1 Fate of the cystic artery at 1-month follow-up
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cholecystectomy does occasionally occur.
Given the potential of gallbladder-related complications,
protective embolization of the cystic artery may be relevant
in circumstances where the location of the cystic artery
would result in direct injection of therapeutic or signiﬁ-
cantly complicate dose planning. Prophylactic emboliza-
tion of the cystic artery has been previously reported,
particularly when the cystic artery demonstrates signiﬁcant
ﬂow, or if catheterization distal to the cystic artery would
lead to inadequate distribution of microspheres [23]. A few
case reports in patients with pseudoaneurysms of the cystic
artery have suggested that proximal coil embolization of
the cystic artery can be performed without clinical sequelae
[24, 25]. Surgical and radiologic reports suggest that tiny
collaterals in the gallbladder fossa often communicate
between the cystic and hepatic arterial circulations [26–28].
Such vessels would effectively render a dual blood supply
to the gallbladder, increasing its tolerance to proximal
embolization (Fig. 4).
Fig. 2 A Initial common
hepatic angiogram demonstrates
conventional origin of the cystic
artery (arrow) and its
characteristic forked
appearance. B Selective cystic
artery angiogram demonstrates
accessory supply to hepatic
parenchyma (open arrow)a s
well as a branch supplying the
abdominal wall (closed arrow).
C Immediately after coil
embolization of the cystic artery
(arrow), no persistent ﬂow is
present. Radioembolization was
performed safely. D Follow-up
proper hepatic angiography
performed 1 month later
demonstrates collateralization to
the coil-embolized cystic artery
(arrow)
Fig. 3 A Initial right hepatic
angiogram demonstrates origin
of the cystic artery (arrow) just
before the division of the right
hepatic artery into anterior and
posterior sectoral branches.
B Selective angiography
conﬁrms gallbladder supply.
C Immediately after Gelfoam
embolization of the cystic
artery, there is cessation of ﬂow
to the gallbladder (arrow).
Radioembolization was
performed safely. D Proper
hepatic angiography 1 month
later demonstrates
recanalization of the cystic
artery (arrow) without
collateralization
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conﬁguration, corresponding to superﬁcial and deep bran-
ches, and by its expected distribution in the gallbladder
fossa. Surgical series demonstrate that the cystic artery
arises conventionally (from the main trunk of the right
hepatic artery) in only approximately half of patients. The
cystic artery often arises more distally in the right hepatic
artery, originating from the anterior sectoral artery in
16–23% of cases, the posterior sectoral artery in 4–5% of
cases, and occasionally from segmental branches [21, 29].
These variants would be expected to be at higher risk
during radioembolization, as right lobar infusion, even with
catheterization deep into the right hepatic artery, would
place the gallbladder in the embolization zone (Fig. 5).
Origin from a replaced or accessory right hepatic artery, or
origin from the left hepatic artery, may also affect radio-
embolization and should be recognized. Some less com-
mon variants, such as proper hepatic, common hepatic,
gastroduodenal, or superior mesenteric artery supply,
would place the cystic artery proximal to the infusion site
and would likely increase the safety margin for
radioembolization.
In this study, we found that protective cystic artery
embolization before yttrium-90 administration is techni-
cally feasible. Despite prior reports of the technical difﬁ-
culty of cystic artery embolization with Gelfoam [23] and
occasional reports of cystic artery perforation [30], embo-
lization was technically achievable in all of our patients
without perforation. Furthermore, cystic artery emboliza-
tion has an acceptable safety proﬁle, with only three
patients reporting clinical symptoms suggestive of chole-
cystitis, and one patient (in the coil embolization group)
requiring cholecystectomy.
The ideal embolic agent for protective embolization of
the cysticartery would provideeffective proximalocclusion
of the cystic artery without deep tissue penetration which
could induce necrosis. Logical choices include coils and
Gelfoam pledgets. Furthermore, the embolic agent should
not result in collateralization of ﬂow to the embolized gall-
bladder, as small collateral vessels would be difﬁcult or
impossible to protect shouldrepeat radioembolization prove
necessary. Persistent occlusion of the cystic artery or
recanalization without collateral formation would each be
acceptable late outcomes. Our study suggests that Gelfoam
pledgets are the embolic agent of choice, as they provided
effective proximal occlusion with a low rate of collateral-
ization, and withoutany instancesof operative cholecystitis.
The ﬁndings of our study may also have implications for
other embolization procedures in the hepatic vasculature.
With the increased potency of carrier-based embolothera-
peutics (such as drug eluting microspheres), minimizing
nontarget embolization has become increasingly essential.
Fig. 4 A Hepatic angiography
demonstrates cystic artery
origin (arrow) from the left
hepatic artery. B Selective
angiography of the cystic artery
demonstrates gallbladder supply
(closed arrows) as well as
multiple communications with
the hepatic arterial circulation
(open arrows)
Fig. 5 Cystic artery origin (arrow) from the anterior sectoral branch
of the right hepatic artery. This variant, occurring in approximately
20% of individuals, places the gallbladder in the treatment zone for
right lobar radioembolization
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embolic agent is not possible or not desired (e.g. wide-
spread disease requiring lobar infusion), or in cases where
an aberrant cystic artery origin places the gallbladder in the
target zone for embolization, prophylactic embolization of
the cystic artery may allow more central administration of
the embolic agent to be performed safely.
In our study, no gallbladder activity was detected on the
planar SPECT scans performed after 99mTc-MAA
administration, and results of the SPECT study did not
inﬂuence cystic artery embolization. The use of SPECT–
computed tomography rather than planar SPECT improves
detection of tracer deposition in the gallbladder [31] and
might therefore serve as a marker for increased risk of
radiation cholecystitis. This warrants further study, as it
may allow selectivity of patients who could most beneﬁt
from prophylactic cystic artery embolization.
Limitations of this study include its relatively small size,
particularly in the coil embolization group, and its retro-
spective nature without case control. Given the historically
low rates of operative cholecystitis reported in the literature
without cystic artery protection, it is not clear if the rate of
cholecystitis would have been different if cystic artery
embolization had not been performed. Also, the clinical
symptoms of the patients could be confounded, as the
patients underwent cystic artery embolization and hepatic
radioembolization concurrently. Finally, angiographic fol-
low-up was only obtained at 1 month; it is uncertain whe-
ther more collateralization of ﬂow to the gallbladder would
have occurred had more time been allowed to elapse.
In conclusion, proximal cystic artery embolization is
safe and feasible and may be performed during liver-
directed embolotherapy to minimize the exposure of the
gallbladder to particulate, chemoembolic, or radioembolic
agents. In our study, Gelfoam pledgets seem to be the
embolic of choice, providing adequate embolization with
delayed recanalization and limited collateral formation.
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